top of page
News, Events and Updates
Search
Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)
Feb 2, 2023
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023
Jan 31, 2023
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 14, 2022
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Dec 1, 2022
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 28, 2022
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Nov 8, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 9, 2022
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022
Aug 3, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results
May 10, 2022
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022
May 3, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 First Quarter Financial Results
Feb 9, 2022
Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, 2/9/2022
Feb 3, 2022
Anavex Life Sciences Promotes Dr. Kaufmann to CSO and Appoints Dr. Hammond as CMO
Jan 6, 2022
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wed., November 24, 2021
Nov 17, 2021
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
Sep 27, 2021
Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
Jun 24, 2021
Anavex Life Sciences Announces $50 Million Registered Direct Offering
Jun 22, 2021
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
